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COST-EFFECTIVENESS OF 
HEPATITIS B VACCINATION IN 
HAEMODIALYSIS PATIENTS 
M W Taal, R van Zyl-Smit 
Background. Vaccination against hepatitis B virus is an 
important means of controlling the infection, but its role in 
haemodialysis patients has been questioned due to the 
latter's impaired immune response. 
M ethods. Forty-eight of 79 haemodialysis patients who w ere 
negative for antibodies to both hepatitis B surface and core 
antigens were entered into a vaccination programme. 
Standard doses of a plasma-derived vaccine were 
administered into the deltoid muscle at 0, 1, 2 and 4 
months, and the antibody response was measured at 1 and 
2 months after the third and fourth doses. 
Results. The peak mean antibody titre of 372 IU / 1 was 
recorded at 1 month after the fourth dose, and the 
maximum response rate was achieved at 2 months after the 
final dose. Seroconversion occurred in 26 of 36 patients 
(72%) who completed the programme, and protective levels 
of antibody above 10 IU / 1 were found in 25 of 36 patients 
(69%). Cost analysis of the project revealed a net saving of ± 
R90/ patient entered at the end of the first year, due to the 
reduced number of patients requiring monthly surveillance 
tests for hepatitis B surface antigen. After that, an annual 
saving of± R380/ patient is projected. 
Conclusion. In view of the high prevalence of chronic 
hepatitis B carriers in the South African population, the 
reduction in the number of patients at risk of infection, 
combined with a net cost saving, makes it reasonable to 
recommend vaccination in all non-immune haemodialysis 
patients despite a reduced response rate. 
5 Afr Med / 20(ll; 91:340-344. 
Hepatitis B virus (HBV) infection is a serious complication for 
the haemodialysis patient and the unit in which he or she 
receives treatment. The infection becomes chronic in about 50% 
of cases'.z and may progress to cause chronic liver disease, 
particularly following renal transplantation.'.:>-7 A high rate of 
nosocomial transmission means that all non-immune staff and 
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patients in the unit are immediately placed at risk of infection. 
Reports of HBV outbreaks in 19% of haemodialysis units in 
the UK, and an annual incidence of infection of 5.6% and 4.4% 
among British and American haemodialysis patients 
respectively,'·" prompted studies which demonstrated that 
regular screening of all patients for hepatitis B surface antigen 
(HBsAg) and isolation of positive patients to separate dialysis 
units were essential in controlling the spread of infection.8•10•11 
The development of a vaccine from HBsAg, obtained from the 
serum of chronic HBV carriers, provided an important new 
method for protecting patients against infection. However, 
although the vaccine induced antibodies in 93 - 100% of staff or 
normal controls,12•15 an impaired response was found in 
haemodialysis patients and seroconversion rates varied from 
55% to 83%."·' .. 23 evertheless, two placebo-controlled studies'2.'9 
demonstrated a reduction in incidence of infection from 45% to 
21% and from 18% to 4% respectively. 
The relatively low seroconversion rate and the associated cost 
have caused some to question the role of hepatitis B vaccine in 
haemodialysis patients. We report here the results of a study to 
investigate the response rate and cos~-effectiveness of 
vaccination in local patients. 
METHODS 
Hepatitis B vaccination 
Chronic haemodialysis patients at Groote Schuur Hospital are 
screened for HBsAg before starting dialysis and positive 
patients are treated in a separate unit. Before the introduction of 
vaccination, negative patients were tested monthly for HBsAg 
as a surveillance measure. In this study, all HBsAg-negative 
patients were tested for antibodies to HBsAg (anti-HBs) and 
immunoglobulin G (IgG) antibodies to hepatitis B core antigen 
(anti-HBc IgG), and those who were negative for both were 
included in the vaccination programme. A plasma-derived 
vaccine containing heat-inactivated HBsAg and aluminium 
phosphate was used (Hepaccine-B Vaccine, Cheil Foods and 
Chemicals Inc.). The standard dose of 3 )lg was administered 
intramuscularly into the deltoid region at 0, 1, 2 and 4 months. 
Anti-HBs antibodies were measured at 1 and 2 months after the 
third dose, and at 1 and 2 months after the final dose (i.e. at 3, 4, 
5 and 6 months after the first dose). Data from studies of 
homosexual men indicate that the minimum antibody level 
required for protection against HBV infection is 10 IU/ 1.,. More 
recently, however, it has been suggested that vaccination 
protocols should aim to maintain antibody levels at> 100 IU/1 
or optimum protection.25 
Patient folders were scrutinised and the following details 
recorded: age, race, gender, time on haemodialysis, number of 
previous blood transfusions and number of previous renal 
transplants. 
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Assay techniques 
HBsAg was detected using a radio-immunoassay (AUSRIA, 
Abbott Laboratories). Antibodies to HBsAg and anti-HBc IgG 
were both measured wit.~ microparticle enzyme immunoassays 
(IMx AUSAB and IMx CORE, Abbott Laboratories). All tests 
were performed by the virology laboratory at Groote Schuur 
Hospital. 
Statistical analysis 
Data for patient age were approximately normally distributed 
and Students !-test was used for testing differences between the 
means of groups. Data for other continuous variables were not 
normally distributed and the Mann-Whitney test was used 
instead. A chi-square (X2) test was used for 2 x 2 tables of 
frequency. P-values of < 0.05 were regarded as significant. 
RESULTS 
HBV antibodies before vaccination 
At the time of pre-vaccination screening, there were 79 HBsAg-
negative patients on chronic haemodialysis. Results of anti-HBs 
and anti-HBc IgG testing are shown in Fig. 1. Twenty-six 
patients (33%) were positive for both antibodies, indicating that 
they had previously been infected with HBV but had cleared 
the virus. Five patients (6%) were positive for anti-HBs but 
negative for anti-HBc, suggesting previous vaccination. An 
analysis of data to test for relationships between previous HBV 
infection and demographic or treatment-related factors is shown 
in Table I. The prevalence of previous infection was 40% in 
black patients, 35% in those of mixed racial origin, and 0% in 
white patients. There w as no difference in the mean age of . 
previously infected and uninfected patients. Males and females 
had a similar prevalence of previous infection. Means for time 
on haemodialysis, number of previous blood transfusions and 
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Fig. 1. HBV antibody status prior to vaccination. 
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Forty-eight patients were negative for both antibodies and 
therefore eligible for vaccination. Three received renal 
transplants before the vaccination was commenced and thus 45 
received the first dose. One patient died, and 8 received renal 
transplants during the study, resul ting in exclusion from the 
vaccination protocol. Therefore 36 received all four doses of 
vaccine and had their antibody response measured. To patients 
reported adverse effects related to vaccination. 
Fig. 2 illustrates the mean antibody titres in those responding 
to the vaccine at differen t time intervals. After the initial three 
doses, the peak geometric mean titre (GMT) of 
279 IU / I was recorded at 1 month after the third dose 
(month 3), although there was a further rise in antibody titre 
from m onth 3 to month 4 in 15 patients. Following the booster 
dose, the peak GMT (372 IU / I) was again noted at 1 month after 
administration (month 5). Most patients had a decline in 
antibody level from month 5 to month 6, and only 4 had a 
further increase. 
Table I. Demographic data and possible risk factors for previous HBV infection in chronic haemodialysis patients 
Total Anti-HBc + Anti-HBc-
umber 79 26 53 
Black 20 8 12 
~~ ~ w ~ 
~~ 7 0 7 
Female 38 11 27 
~ 0 ~ ~ 
Mean age (years) 43.2 (11.8) 44 (9.3) 42.8 (12.9) 
Months on HD" 35 (37.9) 38 (45) 33.5 (34.4) 
Transfusions (units)* 4.6 (7.9) 3.9 (9.3) 5 (7.3) 
Renal transplants* 0.81 (0.92) 0.65 (0.8) 0.89 (0.97) 
• Values for months on HD, transfusion units and renal transplants are expressed as mean (standard deviation). 
t P-value for comparison with white patients. 
l P·vaiue for comparison with males. 
§ P-value for comparison between anti-HBc-positive and negative patients. 
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Fig. 2. Mean antibody titres ±standard deviation at different 
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Fig. 3. Number of patients with antibody response and protective 
antibody levels at different intervals post vaccination. 
Fig. 3 illustrates the number of patients who had responded 
and the number who had achieved the minimum protective 
antibody level of 10 IU / I at different times post-vaccination. 
There was a progressive increase in the number responding and 
the number achieving protective levels from month 3 to month 
6. The maximum response rate was achieved at 2 months after 
the fourth dose of vaccine, when 26 of 36 patients (72%) were 
anti-HBs-positive and 25 of 36 (69%) had achieved protective 
levels. 
Cost analysis of vaccination 
A cost analysis of the vaccination programme was performed 
and results are shown in Table ll. Prices for laboratory 
investigations were based on South African Institute for Medical 
Research (SAIMR) rates for public sector institutions. The cost 
of the vaccine was based on the tender price at Groote Schuur 
Hospital. The total cost of the vaccination programme was R19 
763.00 (± R250/ patient entered). However, this could be 
reduced to R12 853.70 (± R160/ patient) in future by measuring 
antibody response only on one occasion at 2 months after the 
fourth dose of vaccine. Savings result from the fact that patients 
identified to have iinmunity following a previous infection and 
those who develop protective levels of antibodies after 
vaccination, no longer require monthly screening for HBsAg. 
Thus the programme will have resulted in a net saving of R7 
223.90 (± R90/ patient) at the end of the first year. 
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After the first year the cost of maintaining protective antibody 
levels in previously vaccinated patients consists of the cost of an 
annual anti-HBs level and booster doses of vaccine, which 
should be given to those whose levels have dropped below the 
recommen ded level of 100 IU / I. In the current analysis the 
figure of 16 is an estimate based on the number of patients with 
a titre of< 200 IU/ 1 immediately after vaccination, who may be 
expected to have a titre of < 100 IU / I after 1 year. Therefore 
after the first year, antibody screening and vaccination of this 
cohort of patients can be expected to result in an annual net 
saving of R30 092.00 (± R380/ patient entered). 
DISCUSSION 
Response to vaccination 
Using a standard dose of a plasma-derived vaccine given 
intramuscularly at months 0, 1, 2 and 4, we achieved a response 
rate (72%) and peak GMT (372 IU/ 1) similar to that reported by 
other centres. It is difficult to compare results directly because of 
the differences in vaccine type, dose, dosage schedule and 
patient population. However, our resuits are very similar to 
those of Benhamou et al.;z• who used the same schedule, but a 
different plasma-derived vaccine. Previous studies suggest that 
response rates with p lasma-derived (46- 93%)12.13•16•1._20 and 
recombinant vaccines (54- 83%)"·17.n are similar. 
The administration of a booster dose after the initial three 
doses led to an increase in seroconversion rate from 61% to 72% 
and an increase in the number of patients with protective 
antibody levels from 53% to 69%. The peak GMT rose from 
279 IU / I to 372 IU / I. Although these differences are not 
statistically significant, a randomised controlled trial has 
previously demonstrated a significantly improved response 
when a four-dose schedule was compared with the standard 
three-dose schedule in haemodialysis patients."' Shortening the 
dosage schedule by giving the booster dose at 4 months instead 
of 6 months makes the vaccination programme slightly easier to 
manage, and does not appear to affect the response adversely. 
Determination uf the optimum vaccine, dose and schedule in 
haemodialysis patients requires further randomised controlled 
trials. 
Cost-effectiveness of vaccination 
In this study the initial cost of antibody screening and 
vaccination was R250/ patient. The largest component of this 
cost is the antibody assays, which were done repeatedly to 
determine the optimum time for testing in the future. Future 
vaccination programmes will require only pre-vaccination 
testing and a single post-vaccination assay at 2 months after the 
booster dose, which will reduce the cost to approximately 
R160/ patient. The initial costs are offset by the large saving 
resulting from the reduced need for monthly HBsAg testing. 
Therefore by the end of the first year the current programme 
will have resulted in a net saving of R90/ patient. With the use 
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Total cost (1 post-vaccination anti-HBs level) 
Annual cost (after first year) 
Annual anti-HBs level 
Booster dose vaccine 
Saving 
First year 
HBsAg (vaccinated patients with protective levels) 
HBsAg (patients with immunity after infection) 
Annual after first year 
HBsAg (vaccinated patients with protective levels) 
HBsAg (patients with immunity after infection) 
et cost 
First year 
First year {1 post-vaccination anti-HBs level) 
Annual after first year 
'The rand-dollar exchange rate was ±RB.l to the dollar at the time of going to press. 
of only one post-vaccirlation antibody level, the savirlg will be 
Rl80 / patient. After the first year, the cost of maintainirlg 
protective antibody levels is relatively small, and therefore an 
annual saving of R380/patient can be expected. These figures 
do not take irlto account the fact that patients are constantly 
being transplanted and consequently leave the dialysis 
programme. However, the mean time on dialysis at the start of 
the programme was 35 months (Table n, irldicating that the 
majority of patients will be on dialysis long enough for net 
savirlg to occur. 
We observed a zero irlcidence of new HBV infections durirlg 
the 40 months before the vaccination programme, 
Cost/ item Total 






















































- 7 223.90 
- 14 134.10 
-30 092.00 
demonstrating that existing measures to p revent the infection 
were effective. It would therefore be difficult to demonstrate an 
added benefit due to vaccination. evertheless, given the high 
prevalence of HBV carriers ir1 South Africa,'•.27 haemodialysis 
patients remairl at risk of acquirirlg HBV infection ir1 the 
community and secondary transmission to other patients could 
have serious consequences for the individuals affected and for 
the unit as a whole. In order to contairl an outbreak, all infected 
irldividuals would have to be transferred to an isolation unit 
and no new patients could be accepted irlto the unit until there 
was reasonable certairlty that no further seroconversions would 
occur (i.e. for about 6 months). In addition, re-use of all 
m 
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dialysers would have to be discontinued for the same period. 
These measures would severely disrupt the delivery of dialysis 
support to patients and would also lead to grea tly increased 
costs (R200 000 - R300 000) due to the suspension of re-use. 
Therefore it would be important to consider any measure that 
could further reduce the risk of infection. The fact that hepatitis 
B vaccination has minimal adverse effects and results in cost 
saving means that it can be recommended even though the 
response ra te is lower than in healthy subjects and additional 
benefit is difficult to prove in our setting. 
We conclude that all patients should be screened for hepatitis 
B antibodies and vaccinated as required on or before 
commencement of haemodialysis. 
The authors gratefully acknowledge the assistance of Mrs J 
Kannemeyer who performed the antibody assays. 
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HISTORY OF MEDICIN E 
TUMOURS AND CANCERS IN 
GRAECO-ROMAN TIMES 
Francois P Retief, Louise Cilliers 
In Graeco-Roman times all tumours (Greek: onkoi, abnormal 
swellings) were considered to be of inflammatory origin, 
the result of unfavourable humoural fluxes, and caused by 
an extravascular outpouring of fluid into tissue spaces. The 
neop lastic nature of tumours is a more recent concept, 
barely two centuries old. In Hippocratic literature tumours 
were mainly classified as karkinomata, phumata, and oidemata. 
Phumata included a large variety of tumours, inflammatory 
and neoplastic in origin, and mostly benign (in modem 
terms), while oidemata were soft, painless tumours and even 
included generalised oedema (dropsy) . Although all 
categories possibly included occasional cancers, the vast 
majority of what appears to have been malignant tumours 
were called karkinoi karkinomata (Latin: cancrum/carcinoma). 
There was, however, no recognition of benign and 
malignant, primary and secondary tumours, in the modem 
sense. 
5 Afr Med J 2001; 91' 344-348. 
Herodotus tells us that at the turn of the 6th cen tury BC, 
Atossa, the wife of Darius the Great, was cured of a breast 
tumour (phuma) by a captive Greek physician, Democedes. ' The 
readiness with which Democedes promised a cure and the ease 
with which he attained this, points to a benign breast tumour 
rather than a cancer.' The Hippocratic writings mention a 
woman from Abdera who had a breast tumour and a bloody 
discharge from the nipple; she was diagno?ed as having a 
karkinoma and died of the lesion.' This was most likely a cancer 
as we know it today. However, the Graeco-Roman theories of 
tumour formation and carcinogenesis differed radically from 
our modem concepts, which originated as late as the 19th 
century. In the present study the theories of tumour formation 
in antiquity, and the nature of tumours reported, are reviewed. 
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